Argenica Therapeutics (ASX:AGN) patent win sharpens focus on surgery linked stroke

By all accounts, Argenica Therapeutics (ASX:AGN) has already carved out a niche in the high stakes world of neuroprotection, but its latest move signals a tactical pivot with potentially wider clinical and commercial reach.

The Perth-based biotech has been granted a new US patent that extends the application of its lead drug candidate, ARG-007, into one of the most fraught complications in modern surgery: peri-operative stroke.

The patent, number 12,303,550, covers the use of Argenica’s neuroprotective peptides in patients undergoing high-risk operations such as thoracic-aortic repairs and valve replacements.

Procedures where the threat of stroke lingers at rates up to 10% above baseline.

Unlike its broader parent patent, which covers ARG-007’s use across a swathe of neurological traumas including ischaemic stroke and traumatic brain injury, this divisional grant zeroes in on the surgical front a clinical battlefield often overlooked in neuroprotective drug development.

Key Highlights

• New US patent (No. 12,303,550) secured for use of neuroprotective peptides in surgical stroke prevention

• Targeting high-risk operations where stroke risk spikes due to embolic debris

• Builds on parent patent protecting ARG-007 until 2034

• Expands commercial pathways for ARG-007 beyond emergency stroke care

In a field where many drugs have failed to deliver, Argenica Therapuetics strategic positioning of ARG-007 as both a frontline treatment for acute stroke and a prophylactic for surgical patients reflects a nuanced understanding of clinical unmet need and regulatory opportunity.

Managing Director Dr Liz Dallimore noted:

“Our new divisional US patent further strengthens Argenica’s already wide-ranging protection for neuroprotective peptides. Because stroke is a significant complication after cardiac and other major surgeries, the patent creates an additional clinical and commercial avenue for our lead candidate, ARG-007, and expands the overall potential of this promising neuroprotective drug.”

That “additional avenue” could be particularly lucrative.

Unlike ischaemic strokes in emergency settings—which rely on fast diagnosis, specialist intervention, and luck—surgical strokes are predictable risks.

This means prophylactic treatments could be integrated into pre-operative protocols with relative ease, expanding both patient reach and revenue potential.

Next Steps

• Top-line data from Phase 2 ARG-007 stroke trial expected in Q3 2025

• Continued preclinical development in traumatic brain injury and hypoxic ischaemic encephalopathy

• Potential commercial expansion into surgical prophylaxis pending regulatory success

In the race to tame the chaos of cerebral injury, ARG-007 may yet prove to be more than just a reactive remedy.

With regulatory protections stretching to 2034 and a pipeline strategy that bridges the ER and the OR, Argenica is not just playing defence it’s reshaping the offensive line in neuroprotection.